Last updated on April 2018

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel M In BCG Refractory NMIBC


Brief description of study

The purpose of this study is to determine whether NanoxelM is effective in the treatment of patients with recurrent Ta and T1 who experienced treatment failure with at least one prior BCG intravesical treatment.

Clinical Study Identifier: NCT02982395

Contact Investigators or Research Sites near you

Start Over

Ja Hyun Ku, M.D., Ph.D.

Seoul National University Hospital
Seoul, Korea, Republic of
  Connect »